In addition, diffuse gastric cancer had a greater proportion of CLDN18-ARHGAP fusions than intestinal gastric cancer (13.3%, 151/1,138 vs. 1.8%, 8/442; <i>p</i> < 0.001). This evidence concerns the gene CLDN18 and gastric cancer.